Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA profiling of 6xAOM induced colon tumors from wt, miR-34a IEC deficient, p53 IEC deficient and miR-34a/p53 IEC deficient mice

ABSTRACT: P53 induced Mir34a is a tumor suppressor microRNA that plays important roles in cancer related processes such as proliferation, invasion and metastasis. Simultaneous loss of Mir34a and p53 is often observed in CRC. Here we show that, combined deletion of Mir34a and p53 has synergistic effects in suppressing tumor initiation, progression, invasion and metastasis in CRC by using mice lacking Mir34a and p53 in their intestinal epithelium. By in vivo inhibition of IL6R and SERPINE1, which we identified as up-regulated Mir34a targets in tumors of Mir34a/p53 deficient mice, we obtained preclinical evidence for their therapeutic value for treatment of sporadic CRC.

ORGANISM(S): Mus musculus

PROVIDER: GSE99452 | GEO | 2018/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

TGFβ/mutant-p53 jointly controlled genes

Project description:TGFβ ligands act as tumor suppressors in early stage tumors but are paradoxically diverted into potent prometastatic factors in advanced cancers. The molecular nature of this switch remains enigmatic. We now show that TGFβ-dependent cell migration, invasion and metastasis are empowered by mutant-p53. To investigate the specific gene expression program by which mutant-p53 and TGFβ control invasion and metastasis in breast cancer cells, we compared the TGFβ transcriptomic profile of control and mutant-p53 depleted MDA-MB-231 cells. Keywords: expression profiling by array

2009-04-03 | GSE14491 | GEO

mRNA sequencing of human colorectal cancer organoids

Project description:Given that colorectal cancer stem cells (CCSCs) play key roles in the tumor dormancy, metastasis and relapse, targeting CCSCs is a promising strategy in cancer therapy. Here, we aimed to identify new regulators of CCSCs and found that Cullin 4B (CUL4B), which possesses oncogenic properties in multiple solid tumors, drives the development and metastasis of colon cancer by sustaining cancer stem-like features. Elevated expression of CUL4B was confirmed in colon tumors and was associated with poor overall survival. Inhibition of CUL4B in cancer cell lines and patient-derived tumor organoids led to reduced sphere formation, proliferation and metastasis capacity. Mechanistically, CUL4B coordinates with PRC2 complex to repress miR34a expression, thus up-regulates oncogenes including MYCN and NOTCH1, which are targeted by miR34a. Mutation of miR34a binding sites in the 3'UTR of the oncogenes rescues the phenotype caused by CUL4B depletion. Significant correlations were found between expression of CUL4B and miR34a (negatively), miR34a target genes (positively) in clinical samples from colon cancer patients. Collectively, our work demonstrates that CUL4B functions to repress miR34a in maintaining cancer stemness in CRC and provides a potential therapeutic target.

2020-01-14 | GSE143505 | GEO

Pin1/mutant-p53 jointly controlled genes

Project description:To investigate the specific gene expression program by which mutant-p53 and Pin1 control invasion and metastasis in breast cancer cells, we compared the transcriptomic profile of control, mutant-p53 depleted or Pin1 depleted MDA-MB-231 cells.

2011-05-30 | GSE26262 | GEO

Promotion of pancreatic cancer metastasis by mutant p53

Project description:The TP53 transcription factor is frequently mutated at later stages of epithelial cancers, indicating a possible role in their invasion and metastasis. Importantly, in most cases rather than a simple loss of function p53 mutation, point mutations of p53 accumulate at the protein level and may have dominant negative functions. This study analyses gene expression differences between mice harbouring p53 mutation who do and do not develop metastasis. Samples were collected from Genetically modified mice of the genotypes indicated in the characteristics. The presence or absence of metastasis was scored and gene expression differences between the two groups measured.

2015-03-28 | E-GEOD-67358 | biostudies-arrayexpress

Promotion of pancreatic cancer metastasis by mutant p53

2015-03-28 | GSE67358 | GEO

p53 C-terminal acetylation modulates apoptotic program

Project description:Advanced colorectal cancer (CRC) is an unresolved clinical problem. Epigenetic drugs belonging to the group of histone deacetylase inhibitors (HDACi) may combat CRC in rationally designed treatment schedules. Unfortunately, there is sparse evidence on molecular mechanisms and markers that determine cellular sensitivity to HDACi. Irinotecan is widely used to treat CRC and causes replication stress (RS) and DNA damage as topoisomerase-I inhibitor. We applied irinotecan and the class I HDACi entinostat (MS-275) to isogenic p53-positive and -negative CRC cells. Combinations of irinotecan and MS-275 evoke mitochondrial damage, caspase-mediated apoptosis, and RS-associated DNA damage synergistically and p53-dependently. Targeted mass spectrometry and immunoblot show that irinotecan induces phosphorylation, acetylation, and accumulation of p53 and its target genes. Addition of MS-275 augments the irinotecan-induced acetylation of C-terminal lysine residues of p53 but decreases its phosphorylation and p53 target gene induction. Furthermore, MS-275 increases the amount of acetylated p53 at mitochondria and dysregulates the expression of pro- and anti-apoptotic BCL2 proteins in irinotecan-treated cells. Regarding DNA repair, we see that MS-275 represses the homologous recombination (HR) filament protein RAD51, which limits DNA damage and pro-apoptotic effects of irinotecan. These data suggest that key class I HDAC-dependent functions of p53 in cells with RS are linked to mitochondrial damage and a breakdown of HR. Most importantly, combinations of irinotecan plus MS-275 also kill short-term primary CRC cell cultures and organoids from CRC patients but spare organoids of adjacent matched normal tissue. Thus, irinotecan/HDACi treatment is a promising new approach for the therapy of p53-proficient tumors with clinically tractable inhibitors.

2022-02-15 | PXD019999 | Pride

CSF1R mediates effects of miR-34a loss during intestinal tumorigenesis in ApcMin mice (adenoma)

Project description:To address the in vivo relevance of CSF1R regulation by miR-34a during intestinal tumor formation, we generated ApcMin/+ mice with intestinal-epithelial cell (IEC)-specific deletions of the Mir34a and/or Csf1r genes. The mRNA expression profiles of intestinal adenomas with and without functional miR-34a and/or Csf1r were compared.

2022-10-04 | GSE167448 | GEO

shRNAi profiling of human MDA-MB-231 cells expressing anti-p53 (shp53) short-hairpin RNAs treated with TFGbeta or control

Project description:TGFÎ² ligands act as tumor suppressors in early stage tumors but are paradoxically diverted into potent prometastatic factors in advanced cancers. The molecular nature of this switch remains enigmatic. We now show that TGFÎ²-dependent cell migration, invasion and metastasis are empowered by mutant-p53. To investigate the specific gene expression program by which mutant-p53 and TGFÎ² control invasion and metastasis in breast cancer cells, we compared the TGFÎ² transcriptomic profile of control and mutant-p53 depleted MDA-MB-231 cells. Experiment Overall Design: MDA-MB-231 cells, stably expressing either control (shGFP) or anti-p53 (shp53) short-hairpin RNAs, were left untreated or treated with TGFbeta. Samples were then processed for total RNA extraction and hybridization on Affymetrix microarrays. Four biological replicas (A, B, C, D) were used for each of the 4 conditions (1: untreated control; 2: TGFbeta treated control; 3: untreated p53-depleted cells; 4: TGFbeta treated mutant-p53-depleted cells), for a total of 16 samples.

2009-04-11 | E-GEOD-14491 | biostudies-arrayexpress

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Project description:exosomes isolated from: HT29+control shRNA; HT29+p53 shRNA; HCT116 WT p53; HCT116 mutant p53; HCT116 null p53; media used as negative control

2018-02-09 | MSV000082047 | MassIVE

CSF1R mediates effects of miR-34a loss during intestinal tumorigenesis in ApcMin mice (tumor organoid)

Project description:To address the in vivo relevance of CSF1R regulation by miR-34a during intestinal tumor formation, we generated ApcMin/+ mice with intestinal-epithelial cell (IEC)-specific deletions of the Mir34a and/or Csf1r genes. The mRNA expression profiles of tumor organoids derived ffrom intestinal adenomas with and without functional miR-34a and/or Csf1r were compared.

2022-10-04 | GSE167449 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data